Valuation: Haleon plc

Market Cap 30.1B 39.78B 36.11B 33.36B 56.82B 3,717B 58.99B 402B 159B 2,006B 149B 146B 6,337B P/E 2026 *
17.9x
P/E 2027 * 15.9x
Enterprise Value 37.23B 49.22B 44.68B 41.27B 70.29B 4,598B 72.98B 497B 197B 2,481B 185B 181B 7,840B EV / Sales 2026 *
3.3x
EV / Sales 2027 * 3.15x
Free-Float
98.3%
Yield 2026 *
2.35%
Yield 2027 * 2.57%
1 day-1.27%
1 week+2.18%
Current month+7.17%
1 month-8.74%
3 months-2.26%
6 months+2.82%
Current year-8.67%
1 week 340.5
Extreme 340.5
351.6
1 month 310.5
Extreme 310.5
384.1
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 58 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
10/30/26 Buy

Director

7,670 0.0001%
9/22/26 Buy 2,139 0.0000%
9/22/26 Buy 12,209 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%+2.18%-7.36%+4.73% 40.2B
-1.13%-1.17%+38.55%+139.23% 1,275B
-1.36%-0.74%+39.64%+86.06% 680B
-0.59%-0.36%+25.14%+111.73% 521B
-0.76%+1.10%+41.43%+70.96% 389B
-0.75%-3.16%+54.39%+40.90% 356B
-1.83%-0.89%+26.00%+58.48% 305B
-1.65%-0.59%+1.55%+34.52% 287B
-0.95%-1.57%+34.01%+72.55% 250B
+1.60%-0.36%+37.21%+125.66% 208B
Average -0.87%+0.15%+29.06%+74.48% 431B
Weighted average by Cap. -0.98%-0.50%+34.56%+94.77%

Financials

2026 *2027 *
Net sales 11.29B 14.92B 13.55B 12.51B 21.31B 1,394B 22.13B 151B 59.64B 752B 55.99B 54.81B 2,377B 11.66B 15.41B 13.99B 12.93B 22.01B 1,440B 22.86B 156B 61.6B 777B 57.83B 56.61B 2,455B
Net income 1.67B 2.21B 2B 1.85B 3.15B 206B 3.27B 22.29B 8.82B 111B 8.28B 8.1B 351B 1.83B 2.42B 2.19B 2.03B 3.45B 226B 3.59B 24.43B 9.66B 122B 9.07B 8.88B 385B
Net Debt 7.14B 9.44B 8.57B 7.91B 13.48B 882B 13.99B 95.35B 37.71B 476B 35.4B 34.66B 1,503B 6.67B 8.81B 8B 7.39B 12.59B 823B 13.07B 89.05B 35.22B 444B 33.07B 32.37B 1,404B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-11-17 GBX 342.30 -1.27% 28,419,648
26-11-16 GBX 346.70 +0.55% 38,222,705
26-11-13 GBX 344.80 +1.06% 22,389,338
26-11-12 GBX 341.20 +0.59% 42,047,182
26-11-11 GBX 339.20 +1.25% 32,425,649
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.423GBP
Average target price
3.776GBP
Spread / Average Target
+10.30%